MAT for Opioid Addiction: Suboxone, Methadone, and Naltrexone Compared

Medication-assisted treatment (MAT) combines FDA-approved medications with counseling and behavioral therapy to treat opioid use disorder (OUD). MAT is not replacing one addiction with another. It is evidence-based medicine that reduces opioid cravings, prevents withdrawal, decreases overdose death risk by 50% or more, and stabilizes brain chemistry so that recovery is possible.

Three medications are FDA-approved for OUD: buprenorphine (Suboxone), methadone, and naltrexone (Vivitrol). Each works through a different mechanism. Choosing the right one depends on clinical factors, lifestyle considerations, and treatment goals.

Buprenorphine (Suboxone)

Buprenorphine is a partial opioid agonist. It activates opioid receptors enough to prevent withdrawal and reduce cravings but not enough to produce the full euphoric effect of heroin or fentanyl. Suboxone combines buprenorphine with naloxone (an opioid blocker) to discourage injection misuse.

• How it works: Binds to opioid receptors with a ceiling effect. At higher doses, the effect plateaus.
• Prescribing: Can be prescribed by any licensed prescriber in office-based settings (as of the 2023 elimination of the X-waiver requirement).
• Administration: Sublingual film or tablet, taken daily. Monthly injectable form (Sublocade) available.
• Advantages: Can be prescribed and taken at home. Fewer clinic visits required. Lower overdose risk than methadone. Widely available.
• Considerations: Must be in early withdrawal before starting (precipitated withdrawal risk). Not as effective for very high-dose opioid dependence as methadone.

Methadone

Methadone is a full opioid agonist with a long half-life (24 to 36 hours). It fully activates opioid receptors, eliminating cravings and withdrawal for 24 hours or longer. It has the longest track record of any OUD medication, with research dating to the 1960s.

• How it works: Full agonist at opioid receptors. Provides steady-state receptor activation that prevents the highs and lows of short-acting opioid use.
• Prescribing: Initially available only through certified opioid treatment programs (OTPs) with daily observed dosing. Take-home doses are earned over time.
• Administration: Oral liquid or tablet, once daily.
• Advantages: Most effective for severe OUD and high-dose fentanyl dependence. No precipitated withdrawal risk. Long track record of evidence.
• Considerations: Requires daily clinic visits initially. Higher overdose potential than buprenorphine (especially during dose induction). QT prolongation risk at higher doses.

A 2020 systematic review in JAMA Psychiatry found that buprenorphine reduced opioid overdose death by 38% and methadone reduced it by 59% compared to no medication treatment. Both medications also reduced all-cause mortality.

Naltrexone (Vivitrol)

Naltrexone is an opioid antagonist. It blocks opioid receptors completely, preventing any opioid from producing effects. It does not reduce cravings directly but eliminates the reward from use. The extended-release injectable form (Vivitrol) is given once monthly.

• How it works: Blocks opioid receptors for 28 days (injectable) or 24 hours (oral). If someone uses opioids while on naltrexone, they feel no effect.
• Prescribing: Can be prescribed by any licensed prescriber.
• Administration: Monthly intramuscular injection (Vivitrol) or daily oral tablet.
• Advantages: Non-addictive. No diversion potential. Monthly injection eliminates daily medication management.
• Considerations: Requires 7 to 14 days of opioid abstinence before starting (precipitated withdrawal risk). Less effective than buprenorphine or methadone for retention in treatment. Higher overdose risk after discontinuation due to lost tolerance.

Which Medication Is Right?

There is no single best medication. The choice depends on:

1. Severity of dependence: Methadone for severe, high-dose dependence. Buprenorphine for moderate dependence. Naltrexone for people with shorter use histories or strong motivation.
2. Lifestyle factors: Buprenorphine and naltrexone allow greater flexibility. Methadone requires initial daily clinic attendance.
3. Previous treatment: What has worked or failed before guides the choice.
4. Patient preference: Engagement and adherence improve when patients participate in the medication decision.

Finding MAT Providers

SAMHSA’s treatment locator (findtreatment.gov) includes a filter for MAT services. The helpline (1-800-662-4357) can connect you with local MAT providers. Since the X-waiver elimination in 2023, any licensed prescriber can prescribe buprenorphine, expanding access significantly.